OMEICOS Therapeutics GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OMEICOS Therapeutics GmbH
Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.
Appointments: Basliea, BenevolentAI, OMEICOS, Recursion, Takeda UK And Bone Therapeutics Announce New Hires
New appointments have been announced this week by Basilea, BenevolentAI, OMEICOS Therapeutics, Pharnext, Recursion Pharmaceuticals, Sonde Health, Takeda UK, Bone Therapeutics and Glythera.
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Other Names / Subsidiaries
- OMEICOS Ophthalmics, Inc.